Showing 31-40 of 3974 results for "".
Analyzing Safety Data From Level Up
https://practicaldermatology.com/series/the-practical-dermatology-podcast/analyzing-safety-data-from-level-up/33944/The latest news and updates, plus Matthew Zirwas, MD, FAAD, joins Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, to discuss the importance of the Week 16 safety data from the Level Up study on upadacitinib. Silverberg JI, Bunick CG, et al. Efficacy and safety of upadacitinib versuPhysician Spotlight: J. Mark Jackson, MD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-j-mark-jackson-md/23505/Physician Spotlight: Adam J. Friedman, MD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-adam-j-friedman-md/23375/Contact Derm and AD Updates
https://practicaldermatology.com/conferences/maui-derm-2022/contact-derm-and-ad-updates/20052/Matthew Zirwas, MD reviews allergens that have made the list of Allergen of the Year over the program's 20-year history and what dermatologists should know about these allergens. He also provides an overview of his approach to diagnosing and treating atopic dermatitis.Physician Spotlight: Adam J. Friedman, MD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-adam-j-friedman-md-1/23614/Updates from CSF 2017
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-updates-from-csf-2017/18371/Dermatologists and core cosmetic physicians shared new insights and reviewed the developments in clinical and cosmetic dermatology at the ninth annual Cosmetic Surgery Forum in Las Vegas. Matthew Zirwas, MD addressed interest in oral supplements to support skin health. Neurotoxin pioneer Nick Lowe,Physician Spotlight: George J. Hruza, MD, MBA, FAAD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-george-j-hruza-md-mba-faad/23062/Clinical Conversations: How JAK Inhibitors are Changing the AD Treatment Landscape
https://practicaldermatology.com/series/jak-inhibitors-in-practice/clinical-conversations-how-jak-inhibitors-are-changing-the-ad-treatment-landscape/20092/With the approval of JAK inhibitors to treat eczema, the treatment landscape is changing. Matt Zirwas, MD and Adelaide Hebert, MD talk about the role for JAK inhibitors and key considerations for discussing options with patients.Clinical Conversations: Risks vs Benefits of JAK Inhibitors
https://practicaldermatology.com/series/jak-inhibitors-in-practice/clinical-conversations-risks-vs-benefits-of-jak-inhibitors/20108/Clinical data for JAK inhibitors show clear benefits for many patients. But these drugs are associated with certain risks and class warnings. Matt Zirwas, MD and Adelaide Hebert, MD describe how they weigh risks, educate patients, and optimize long-term management.Fractional Lasers for NMSC and More
https://practicaldermatology.com/conferences/scale-2025/fractional-lasers-for-nmsc-and-more/35876/Joel L. Cohen, MD, FAAD, and Matthew M. Avram, MD, talk about research involving fractional lasers, including as part of combination treatments for nonmelanoma skin cancer, at Music City SCALE 2025.